US5871010A - Inhaler apparatus with modified surfaces for enhanced release of dry powders - Google Patents
Inhaler apparatus with modified surfaces for enhanced release of dry powders Download PDFInfo
- Publication number
- US5871010A US5871010A US08/661,213 US66121396A US5871010A US 5871010 A US5871010 A US 5871010A US 66121396 A US66121396 A US 66121396A US 5871010 A US5871010 A US 5871010A
- Authority
- US
- United States
- Prior art keywords
- inhaler
- substrate
- inhaler apparatus
- medicament
- mouthpiece
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
- A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
- A61M15/0046—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier
- A61M15/0051—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters characterized by the type of carrier the dosages being arranged on a tape, e.g. strips
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0233—Conductive materials, e.g. antistatic coatings for spark prevention
Definitions
- the present invention provides an inhaler apparatus comprising interior surfaces having contact with a medicament for inhalation, the interior surfaces including the interior of the mouthpiece and the substrate with medicament deposited thereon.
- the interior surfaces including the interior of the mouthpiece and the substrate with medicament deposited thereon.
- at least one of such interior surfaces have indentations or raised areas therein, the raised areas having valleys between them.
- WO 93/09832 discloses an inhalation device having an elongate carrier of medicament powder, the medicament powder being released after impact from a hammer, the inhalation device having a convoluted channel to deagglomerate the medicament powder.
- the disadvantages of the inhalers of the prior art include, for example, the inability of a patient suffering from a respiratory disorder, such as asthma, to inhale with sufficient force to receive an entire dosage.
- a patient may only be able to generate an air flow rate of about 15 liters per minute.
- the patient's inhalation supplies the energy required to dispense the medicament from the inhaler.
- the air flow rate generated by the patient's lungs significantly affects the amount of medicament that ultimately exits the inhaler and reaches the lungs.
- Another disadvantage of the inhalers of the prior art includes the inability to accurately determine the amount of medicament dispensed, since the inhaler may dispense a greater or lesser amount of medicament, depending upon the patient's air flow rate, for example.
- a further disadvantage of the inhalers of the prior art is a problem of agglomeration of the medicament powder. Agglomerated particles generally impact the mouth and throat rather than remaining in the air flow for deposition on the lungs.
- One of the approaches to remedying this problem has been the provision of tortuous channels in the inhalers of the prior art to promote deagglomeration. This approach suffers from drawbacks, however, such as the deposition of the medicament along the channels, thereby leading to inaccurate dosage dispensing.
- the present invention is directed, in part, to an inhaler apparatus comprising interior surfaces having contact with a medicament for inhalation, the interior surfaces including an interior surface of a mouthpiece and a substrate with medicament deposited thereon, at least one of such interior surfaces comprising indentations or raised areas therein, the raised areas having valleys therebetween.
- the interior surface is a surface on a substrate having medicament deposited thereon, and in other preferred embodiments, the interior surface is an interior surface of the mouthpiece of the inhaler.
- both the surface of the substrate and the mouthpiece and any other surfaces having contact with the medicament have indentations or raised areas therein, or any other surface structure for decreasing the area of contact between the selected medicament and the surface.
- the width of the indentations or valleys have a diameter that is about 5% to about 20% smaller and more preferably, about 10% to about 20% smaller than a minimum selected particle size to be administered by the inhaler. In certain preferred embodiments, the width of the indentations or valleys have a diameter of about one micron to about 2.5 microns.
- the depth of the indentations or valleys is also smaller than a minimum selected particle size to be administered by the inhaler, and most preferably, the depth is about 5% to about 50% smaller, and more preferably, about 5% to about 20% smaller than a minimum selected particle size to be administered by the inhaler.
- the indentations or valleys are substantially regularly spaced throughout the area of the substrate having medicament thereon or throughout the mouthpiece of the inhaler. In certain preferred embodiments, the indentations are substantially linear.
- the substrate having the medicament deposited thereon can be of any selected shape, including, in preferred embodiments, a disk or a tape.
- the substrate comprises multiple dosage units of medicament.
- the medicament is sealed onto the substrate.
- the surfaces are preferably made of a material having a low surface energy, and more preferably, also having, when uncharged, no substantial van der Waals or electrostatic interaction with the medicament. Furthermore, the material is preferably substantially chemically unreactive with the medicament. Examples of materials that can be used for such surfaces include perfluorinated polymers such as polytetrafluoroethylene (“TEFLON”), silicone, silicon alumina ceramic, polymeric photoconductor, polycarbonate, polyimide, polypropylene and polyethylene.
- TEFLON polytetrafluoroethylene
- the surface has reacted with a silane, such as fluorosilane or aminosilane, to form a film having a low surface energy.
- a silane such as fluorosilane or aminosilane
- the surface can be treated to apply a perfluorinated polymer film.
- an inhaler apparatus comprising a mouthpiece, the mouthpiece having a wall with an exterior and an interior surface, the mouthpiece further comprising multiple air inlets extending from the exterior to the interior, the inlets each being in communication with a channel, each channel extending from the interior to the exterior of the mouthpiece.
- each channel is positioned at an angle of about 20 to about 70 degrees, and more preferably, about 45 degrees from the wall of the mouthpiece.
- the channels are substantially cylindrical in shape.
- the channels are preferably less than about 5 mm in diameter, such as about 0.1 to about 5 mm in diameter or less than about 0.1 mm in diameter.
- the interior surface of the mouthpiece further comprises indentations or raised areas therein, the raised areas having valleys therebetween, and the indentations or valleys are preferably substantially parallel to the direction of air flow in the mouthpiece during inhalation.
- the width of the indentations or valleys is about 5% to about 20% smaller, and more preferably, about 10% to about 20% smaller than the minimum particle size to be administered by the inhaler.
- the mouthpiece further comprises a shuttering mechanism for selectively closing at least one of the air inlets, such shuttering action preferably being capable of actuation by the patient.
- the present invention provides a method of manufacturing an inhaler apparatus, comprising:
- the deposition Is performed electrostatically.
- the medicament deposited on the substrate has a particle size of about one to about fifteen microns.
- the methods of the invention include sealing the substrate having medicament deposited thereon.
- FIG. 1 is a graphical representation of 3 forces that adhere particles to the substrate of the inhaler; electrostatic forces (“Fe”), charge imaging forces (“Fim”) and van der Waals forces (“Fv”).
- FIGS. 2A-E are micrographs of release of a powder from a polypropylene substrate with indentations therein, in the form of grooves.
- the magnification shown in FIGS. 2A-E is 42 ⁇ .
- FIG. 2A shows the powder before release;
- FIG. 2B shows the powder remaining after being subjected to an air flow of 15 liters per minute;
- FIG. 2C shows the powder remaining after being subjected to an air flow of 30 liters per minute;
- FIG. 2D shows the powder remaining after being subjected to an air flow of 45 liters per minute;
- FIG. 2E shows the powder remaining after being subjected to an air flow of 57 liters per minute.
- FIG. 2F is a graphical representation of data obtained for the release of powder from the substrate shown in FIGS. 2A-E at increasing flow rates.
- FIGS. 3A-C are photomicrographs of an inhaler substrate.
- FIG. 3A is a photomicrograph of a polypropylene substrate with indentations therein, in the form of grooves;
- FIG. 3B is a micrograph of the same substrate with powder deposited thereon, and
- FIG. 3C is a micrograph of the same substrate after release of the powder.
- FIGS. 4A-C are photomicrographs of an inhaler substrate made of silicon with grooved indentations in the surface as the substrate.
- FIG. 4A is a photomicrograph of the substrate;
- FIG. 4B is a micrograph of the same substrate with powder deposited thereon, and
- FIG. 4C is a micrograph of the same substrate after release of the powder.
- FIGS. 5A-C show a higher magnification of the photomicrographs of FIGS. 4A-C.
- FIGS. 6A-C show a higher magnification of the photomicrographs of FIGS. 5A-C.
- FIG. 7 is a photograph of an embodiment of a mouthpiece of an inhaler of the invention, the arrow pointing to the air inlets of the mouthpiece.
- FIGS. 8A and 8B are cross-sectional views of one embodiment of the inhaler apparatus of the invention.
- FIG. 8A shows the inhaler without an electronic assisting means
- FIG. 8B shows the inhaler with an electronic assisting means.
- FIG. 9 is a photograph of a set-up used to test release of the powder from the substrate of an inhaler.
- FIG. 10 is a graphical representation of the amount of medicament powder released from a planar substrate as compared to a substrate with grooved indentations therein.
- the powder After depositing a powder onto a substrate of an inhaler, the powder must be accurately released upon inhalation by a patient.
- One of the obstacles to overcome is the adherence of the powder particles to the substrate.
- One of the forces holding the particles onto the substrate is a van der Waals force.
- Another one of the holding forces is the electrostatic force.
- a third holding force is a charge image force, generated by the charge of the powder particle in the local area of the substrate upon which it is adhered.
- These forces vary in magnitude depending upon, for example, the conductivity of the substrate.
- the van der Waals attraction increases over time, and the rate of increase is related to the rate of particle deformation due to greater contact area. Furthermore, these forces increase as the particle size increases. See, for example, FIG. 1, which is a graphical representation of mathematical calculations of the foregoing forces.
- the present invention provides for inhalers with modified substrates which alter the attractive forces.
- greater than about 70%, and preferably greater than about 80% of the medicament is released upon inhalation.
- the air flow required for release of about 80% to about 100% of the medicament in a dosage unit is less than about 60 liters per minute; more preferably, less than about 30 liters per minute, and even more preferably, no greater than about 15 liters per minute. See, for example, FIGS.
- FIG. 2A-E which show release of a medicament from a textured substrate having grooved indentations at 15 liters per minute (B), 30 liters per minute (C), 45 liters per minute (D), and 57 liters per minute (E).
- FIG. 2F is a graph of the data obtained and which shows the increasing release of medicament from the substrate as air flow increases.
- Example 1 provides the data used to generate the graph shown in FIG. 2F.
- the deposition technique used in this example involved ion printing according to Ser. No. 08/471,889.
- an electrostatic chuck is used to deposit electrostatically charged medicament onto the inhaler substrate, as described, for example, in U.S. Ser. No. 08/630,050.
- a preferred deposition technique, using an electrostatic chuck is believed to result in a higher percentage of release of the medicament from the inhaler substrate.
- Other deposition techniques can also be used with the modified inhaler substrates of the invention.
- the inhaler substrate is preferably modified to minimize the surface area of the contact between the particles of the powder and the surface of the substrate, for those particles having a selected size. Particles having the desired size will have minimal contact with the substrate, and will therefore be more likely to be released from the substrate.
- the modified substrate can be configured so that particles having an undesirable size are trapped. For example, if the surface area of contact between the particle and the substrate is high, such as with a particle having a size below the selected size, the higher contact leads to trapping the particle on the substrate rather than releasing it.
- the minimization of the area of contact is preferably accomplished in the following ways.
- the surface area of contact can be minimized, for example, by providing indentations in the plane of the surface, or by providing raised areas in the plane of the surface.
- at least one interior surface of the inhaler has indentations or raised areas with valleys therebetween, or other surface modification for decreasing the area of contact between the selected medicament particles and the interior surface of the inhaler in contact with the medicament.
- the contact of the medicament with the surface can occur, for example, before inhalation or during inhalation, such as contact with the substrate during deposition before inhalation, or contact with an interior surface of the mouthpiece during inhalation.
- both the surface of the substrate upon which medicament is deposited and the mouthpiece and any other surfaces having contact with the medicament have indentations or raised areas therein, or any other surface structure for decreasing the area of contact between the selected medicament and the surface.
- the indentation or raised area may be, for example, linear, tortuous, curved, circular, or any other desired configuration.
- the indentations are in the form of linear grooves, which provides, for example, for ease of manufacturing. See, for example, FIGS. 3A-C, which show release from a polypropylene substrate having grooved indentations.
- FIG. 3A is a micrograph of the substrate, which has grooved indentations therein, prior to deposition.
- FIG. 3B is a micrograph of the substrate of FIG. 3A after deposition of the medicament powder thereon.
- FIG. 3C is a micrograph of FIG. 3B after release of the medicament from the substrate. See, also, for example, FIGS. 4-6 which show three increasing magnifications of release from silicon.
- FIG. 4 has the lowest magnification
- FIG. 5 has an intermediate magnification
- FIG. 6 has the highest magnification.
- a 100 micron bar is provided in FIGS. 4 and 5 for size reference
- a 10 micron bar is provided in FIG. 6 for size reference.
- Part A of each of these figures is a photomicrograph of the substrate before deposition.
- Part B of each of these figures is a photomicrograph of the substrate after deposition of the medicament powder.
- Part C of each figures is a photomicrograph of the substrate after release of the powder.
- the depth of an indentation or the height of a raised area is slightly smaller than the size of the smallest particle desired to released from the inhaler, such as about 5% to about 50% smaller, and more preferably, about 5% to about 20% smaller than the smallest selected particle.
- the width of the indentation or the valley between two raised areas is preferably slightly smaller than the diameter of the smallest particle selected to be released, such as about 5% to about 20% smaller, and more preferably, about 10% to about 20% smaller.
- the width of the indentation or valley will preferably be about 1.8 microns.
- the diameter of the indentation or valley is less than the diameter of the minimum respirable medicament particle size.
- the pitch of the substrate, measured from the center of a valley to the center of a raised area is preferably about 1 to about 2.5 microns for dispensing particles from about 2 to about 6 microns.
- Particle size can be determined, for example, using scanning electron microscopy.
- the surface area of the contact between the medicament and the substrate may be decreased, for example, by using a perforated substrate.
- more than one such modification may be made to a single substrate.
- the entire surface area of the surface in contact with the powder particles is modified to have minimized contact with the medicament powder.
- a further aspect of the present invention is the use of a selected material to form the surface of the substrate in contact with the powder particles.
- the material is selected in part on the basis of low surface energy. See, for example, Kaelble, Physical Chemistry of Adhesion at pages 149-164 (John Wiley & Sons 1971), which is hereby incorporated by reference herein in its entirety.
- the surface energy of the surface in contact with the powder particles is between about 10 to about 25 dynes/cm. More preferably, the surfaces, when uncharged, have no substantial van der Waals or electrostatic interaction with the medicament.
- the material is preferably substantially chemically unreactive with the medicament.
- perfluorinated polymers such as polytetrafluoroethylene (“TEFLON"), silicone, silicon alumina ceramic, polymeric photoconductor, polycarbonate, polyimide, polypropylene and polyethylene.
- TEFLON polytetrafluoroethylene
- silicone silicone
- silicon alumina ceramic polymeric photoconductor
- polycarbonate polycarbonate
- polyimide polypropylene
- polyethylene polyethylene
- the surface has reacted with a silane, such as fluorosilane or aminosilane, to form a film having a low surface energy.
- the surface can be treated to apply a perfluorinated polymer film. See, for example, U.S. Pat. No. 4,252,848, which is incorporated by reference herein in its entirety.
- the material forming the surface in contact with the powder particles is also preferably selected on the basis of low chemical reactivity with the powder particles. For example, if the powder to be deposited upon the substrate is a charged or polar particle, the surface of the substrate is preferably not charged or polar.
- the materials used to form the surfaces in contact with the medicament are preferably selected to minimize the van der Waals and electrostatic adhesion of the medicament, as well as to minimize chemical reactivity.
- the material used to form the surface in contact with the medicament is preferably hard, and not pliable, particularly since pliability tends to increase contact area. See, for example, Nielsen, Mechanical Properties of Polymers and Composites (Marcel Dekker Inc., NY 1974) at pages 367-369, which is hereby incorporated by reference herein in its entirety.
- the material has a Vickers hardness greater than about 10 kp/mm 2 , such as polystyrene, polymethyl methacrylate, polycarbonate, polyacetal, polyethylene terephthalate and phenolic resin.
- the material used to make a surface in contact with the medicament is a polymer.
- Preferred materials for use in such surfaces include polytetrafluoroethylene, silicon, alumina ceramic, aluminized organic photoconductor, polyvinyl carbazole, polycarbonate, polyimide and polyethylene.
- the indentations are the grooves present in an alumina ceramic printed board. See, for example, FIGS. 4-6.
- a die stamp having 2 micron spaced grooves is used to emboss a substrate, thereby creating a substrate with the desired indentations therein. See, for example, FIG. 3.
- the surface is treated with a silane, such as fluorosilane or aminosilane.
- a silane such as fluorosilane or aminosilane.
- polyimide is not preferred since in some instances, it may adhere a powder due to a chemical or electrostatic interaction.
- the materials used and the surface treatment, if any, are pharmaceutically acceptable and do not cause substantial toxicity.
- the size and shape of the substrate can be selected based upon the application.
- the substrate will be in the form of a disk or elongated such as a tape.
- multiple dosage units are deposited onto the substrate, each dosage unit being in a discrete area, separated by an area of the substrate having no powder deposited thereon.
- the substrate is sealed for protection, such as against the environment, including humidity, as well as for sterility
- the advantages of the inhaler apparatus of the present invention include its operation in releasing powder without the use of mechanical force, such as a hammer.
- the requirement of mechanical force to release the powder may mean that the powder is unintentionally released, for example, upon dropping the inhaler.
- the inhalers of the present invention are designed for release of the medicament powder upon inhalation, preferably they do not release the medicament prior to inhalation.
- the medicament will remain on the substrate after the inhaler apparatus is subjected to a drop test, such as dropping the inhaler into a tube from a height of about 48 inches at a temperature of about 65 degrees Celsius and a relative humidity of about 65%.
- the inhaler apparatus further includes a mouthpiece with a configuration that prevents adherence of the medicament powder
- the mouthpiece preferably has an interior surface that is selected to resist adhering the powder particles.
- the interior surface preferably has indentations or raised areas thereon, such as the modifications described above, to promote release of the powder.
- the surface area of the interior surface of the mouthpiece is increased by using indentations in the form of grooves that are parallel to the direction of air flow in the mouthpiece, preferably causing substantially laminar air flow.
- the mouthpiece has multiple air inlets with a channel connected to each inlet for the enhancement of release of medicament powder. See, for example, FIG. 7, in which the arrows point to the inlets.
- the channel connects the interior of the mouthpiece to the ambient atmosphere through an opening termed an "air inlet hole.”
- the air inlet hole is created, such as drilled, at an angle, preferably about 20 to about 70 degrees, and more preferably, about 45 degrees.
- each channel extends from the corresponding air inlet at an angle of about 20 degrees to about 70 degrees. More preferably, the channel forms an angle of about 45 degrees from the horizon.
- the channels are cylindrical and have a diameter of less than about 5 mm, such as about 0.1 to about 5 mm.
- the mouthpiece is configured to maximize air flow between the powder and the substrate so that the powder is readily released from the substrate upon inhalation.
- the air inlets can be opened and closed at will by the patient, or automatically via a shuttering mechanism, to maintain a constant pressure drop regardless of the air flow.
- FIGS. 8A and 8B Illustrations of embodiments of the inhaler apparatus of the invention having multiple air inlets with channels connected to each inlet are provided in FIGS. 8A and 8B.
- FIG. 8A shows a mouthpiece 94 with air inlets 82 having channels 83 attached thereto.
- a shuttering mechanism 84 is provided for several of the air inlets.
- the mouthpiece 94 is in air flow communication with the substrate 86 having medicant 87 deposited thereon.
- the substrate 86 is in the form of an elongated tape, which is provided by reel 92 and taken up by reel 90.
- the substrate has a seal (not shown) which is taken up by reel 88.
- FIG. 8B illustrates the inhaler of FIG. 8A, further including an electronic release mechanism (not shown) powered by a battery 96.
- each air inlet is connected via the channel to a portion of an individual dosage.
- a dosage of 100 micrograms can be administered by aligning each of four 25-microgram dosages with each of four air inlets.
- the apparatus is preferably used with the medicament deposited in the desired particle range, and since in preferred embodiments, a substantial amount of undesired particle size range may be trapped on the substrate, there may be no need for additional devices to promote deagglomeration.
- the present invention provides advantages over inhalers requiring devices to deagglomerate, such as tortuous channels, that can trap medicament.
- the size of the particles dispensed by the inhaler is no greater than about 15 microns, and more preferably, no greater than about 10 microns.
- the substrate of the inhaler is equipped with a conductive layer for electronic assistance of release of the powder, as described in co-pending application entitled “Inhaler Apparatus with an Electronic Means for Enhanced Release of Dry Powders", filed simultaneously herewith.
- the inhaler can also be equipped with other mechanisms for enhancing release, including an electron emitter such as a diamond tip emitter or other electron emitter, in order to neutralize the charge holding the powder onto the substrate.
- an electron emitter such as a diamond tip emitter or other electron emitter
- the substrate upon which the medicament is deposited may be a photoconductive substrate that releases the medicament upon the application of light.
- the inhalers of the invention can be used with numerous types of medicaments, and in addition to oral administration, the inhalers of the invention can be used with nasal administration.
- a modified polypropylene substrate, as shown in FIG. 3 was tested for release of a powdered medicament, mometasone furoate.
- a 2 cm 2 square of substrate was first weighed in milligrams on a microbalance ("sub(mg)"). Then, powdered medicament was deposited on the substrate, using the ion printing technique disclosed in U.S. Ser. No. 08/471,889. The medicament was deposited in four dots, using several bursts of air to dispense a powder cloud. Next, the substrate was weighed with the medicament thereon ("sub+drug," which is provided in mg).
- the weight of the medicament (“drug(mg)”) was determined by substracting the weight of the substrate before deposition (“sub(mg)”) from the weight of the substrate after deposition ("sub+drug”). Two weight measurements were taken for each data point, and the two weight measurements were averaged ("average").
- the substrate was placed in an apparatus such as that shown in FIG. 9, and an inhaler mouthpiece was attached to the cylinder 98.
- the inhaler mouthpiece included 8 air inlets, each having a channel (capillary tubes) at a 45 degree angle from the mouthpiece to enhance lift off of the medicament powder.
- the release of the powder from the substrate was tested at four different flow rates of air applied to the substrate through the mouthpiece; 15, 30, 45 and 57 liters per minute. "Flow rate” indicates the air flow rate used to release the medicament from the inhaler.
- the substrate was weighed after release of the drug ("sub-drug," which is indicated in mg).
- the percentage of drug released from the substrate (“%drug") was determined using the weight of the drug left after release and the weight of the drug before release. "Humid./temp” indicates the percentage of humidity and ambient temperature (degrees Farenheit) at the time of the testing.
- FIG. 9 The release of medicament from an inhaler substrate having medicament deposited thereon was tested using the apparatus shown in FIG. 9.
- air flow was generated through the use of a vacuum (not shown) attached to tubing 97, which was in turn attached to a cylinder 98, for attachment to an inhaler mouthpiece (not shown).
- the mouthpiece including 8 air inlets, each having a channel (capillary tubes) at 45 degree angles to the mouthpiece.
- a flow meter 99 was used to measure the rate of air flow.
- Three samples of each of two different substrates were tested, the first substrate having a grooved surface, as shown in FIG. 3, and the second substrate having an unmodified planar surface. Both substrates were made of polypropylene. The results of the testing are shown in Table 4 below.
- FIG. 10 shows that release of the medicament from the substrate with indentations in the form of grooves was much higher than the release from an unmodified substrate.
Abstract
Description
TABLE 1 __________________________________________________________________________ sub + drug sub (mg) drug(mg) sub-drug Drug left % drug flow rate humid./ Sample # appl/psi (mg) substrate (mg) after dispensing (mg) dispensed (liters/min) temp./ __________________________________________________________________________ 1 5/7.5 8.7735 8.6095 8.6494 57 68/81 8.7735 8.6092 8.6495 average 8.7735 8.60935 0.16415 8.64945 0.0401 75.57112 2 5/7.5 7.2482 7.1406 57 67/81 7.2486 7.1409 average 7.2484 7.14075 0.10765 7.16 0.01925 82.11797 8.2274 3 4/7.5 8.3174 8.1912 8.2257 n/d 68/81 8.3161 8.1911 8.2238 average 8.31675 8.19115 0.1256 8.225633333 0.0344833 72.54512 4 4/7.5 6.8848 6.7813 n/d 68/81 6.8844 6.7816 average 6.8846 6.78145 0.10315 n/d 5 5/7.5 8.7858 8.681 45 68/81 8.7862 8.682 average 8.786 8.6815 0.1045 8.7215 0.04 61.72249 6 3/7.5 7.6297 7.5486 7.5782 n/d 68/90 7.63 7.547 7.582 average 7.62985 7.5478 0.08205 7.578133333 0.0303333 83.03067 7 4/7.5 8.1118 7.9899 15 68/90 8.1117 7.9905 average 8.11175 7.9902 0.12155 6.3 8 5/7.5 7.517 7.4066 30 68/90 7.5168 7.4063 average 7.5169 7.40645 0.11045 7.4913 0.08485 23.17791 __________________________________________________________________________
TABLE 2 __________________________________________________________________________ sub (mg) sub + drug drug(mg) sub-drug Drug left % drug flow rate humid./temp Sample # appl/psi (samp + subs) substrate (mg) after dispensing (mg) dispensed (liters/min) temp (F)t __________________________________________________________________________ 9 6/7.5 7.0404 6.9084 6.9337 60 67/83 7.0408 6.9086 6.9344 average 7.0406 6.9085 0.1321 6.93405 0.02555 80.658592 10 4/7.5 7.5945 7.4758 7.5067 45 66/83 7.5938 7.4765 7.507 average 7.59415 7.47615 0.118 7.50685 0.0307 73.983051 11 3/7.5 8.037 7.9513 8.037 15 66/83 8.0371 7.9514 8.0366 average 8.03705 7.95135 0.0857 8.0368 0.08545 0.2917153 12 4/7.5 8.8213 8.7376 8.8202 15 65/83 8.8207 8.7375 8.8212 average 8.821 8.73755 0.08345 8.8207 0.08315 0.3594967 13 5/7.5 7.1802 7.1081 7.1794 15 65/83 7.1796 7.1081 7.1795 average 7.1799 7.1081 0.0718 7.17945 0.07135 0.6267409 14 3/7.5 6.8602 6.7494 6.8293 30 70/84 6.8597 6.7485 6.8294 average 6.85995 6.74895 0.111 6.82935 0.0804 27.567568 15 5/7.5 9.3052 9.1824 9.2381 45 70/86 9.305 9.1825 9.238 average 9.3051 9.18245 0.12265 9.23805 0.0556 54.667754 16 5/7.5 8.983 8.8723 8.9582 30 71/86 8.9845 8.8727 8.958 average 8.98375 8.8725 0.11125 8.9581 0.0856 23.05618 17 7/7.8 9.3624 9.2077 9.2326 60 70/86 9.3623 9.2081 9.2324 average 9.36235 9.2079 0.15445 9.2325 0.0246 84.072515 __________________________________________________________________________
TABLE 3 __________________________________________________________________________ flow rate 57 45 30 15 __________________________________________________________________________ 80.658592 54.6677538 27.5675676 0.29171529 84.0725154 73.9830508 23.0561798 0.3594967 82.1179749 61.722488 23.1779086 0.62674095 average 82.28302743 63.4577642 242.600552 0.425984313 standard deviation 1.712936076 9.773871401 2.570231634 0.177132719 80.658592 54.6677538 27.5675676 0.29171529 w/ one data point 84.0725154 23.0561798 0.3594967 dropped 82.1179749 61.722488 23.1779086 0.62674095 average 82.28302743 58.1951209 24.600552 0.425984313 standard deviation 1.712936076 4.988450392 2.570231634 0.177132719 __________________________________________________________________________
TABLE 4 ______________________________________ % medicament % medicament released released Sample number from grooved substrate from planar substrate ______________________________________ 1 80.5 62 2 84 64.5 3 82 67 Average Value 82.16 64.5 Standard 1.84 2.5 Deviation ______________________________________
Claims (31)
Priority Applications (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/661,213 US5871010A (en) | 1996-06-10 | 1996-06-10 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
JP50181298A JP3436542B2 (en) | 1996-06-10 | 1997-06-10 | Inhalation device with modified surface for enhanced dry powder release |
DE69730970T DE69730970D1 (en) | 1996-06-10 | 1997-06-10 | INHALATOR WITH MODIFIED SURFACES FOR IMPROVED DELIVERY OF DRY POWDERS |
AT97929947T ATE277657T1 (en) | 1996-06-10 | 1997-06-10 | INHALER WITH MODIFIED SURFACES FOR IMPROVED DELIVERY OF DRY POWDERS |
IL12744997A IL127449A0 (en) | 1996-06-10 | 1997-06-10 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
NZ332962A NZ332962A (en) | 1996-06-10 | 1997-06-10 | Inhaler apparatus with modified surfaces for enhanced release of dry powders that are electrostatically charged |
CA002254928A CA2254928C (en) | 1996-06-10 | 1997-06-10 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
PCT/US1997/010162 WO1997047347A1 (en) | 1996-06-10 | 1997-06-10 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
AU33889/97A AU712557B2 (en) | 1996-06-10 | 1997-06-10 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
EP97929947A EP0917476B1 (en) | 1996-06-10 | 1997-06-10 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US09/210,214 US6298847B1 (en) | 1996-06-10 | 1998-12-11 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US09/782,419 US6591833B2 (en) | 1996-06-10 | 2001-02-13 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/661,213 US5871010A (en) | 1996-06-10 | 1996-06-10 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/210,214 Continuation US6298847B1 (en) | 1996-06-10 | 1998-12-11 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
Publications (1)
Publication Number | Publication Date |
---|---|
US5871010A true US5871010A (en) | 1999-02-16 |
Family
ID=24652645
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08/661,213 Expired - Fee Related US5871010A (en) | 1996-06-10 | 1996-06-10 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US09/210,214 Expired - Fee Related US6298847B1 (en) | 1996-06-10 | 1998-12-11 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US09/782,419 Expired - Fee Related US6591833B2 (en) | 1996-06-10 | 2001-02-13 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/210,214 Expired - Fee Related US6298847B1 (en) | 1996-06-10 | 1998-12-11 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US09/782,419 Expired - Fee Related US6591833B2 (en) | 1996-06-10 | 2001-02-13 | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
Country Status (1)
Country | Link |
---|---|
US (3) | US5871010A (en) |
Cited By (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999063972A1 (en) | 1998-06-10 | 1999-12-16 | Delsys Pharmaceutical Corporation | Pharmaceutical product and methods and apparatus for making same |
WO2000027456A1 (en) | 1998-11-05 | 2000-05-18 | Delsys Pharmaceutical Corporation | Method of depositing a dry powder and dispensing device |
US6138671A (en) * | 1994-10-04 | 2000-10-31 | The Procter & Gamble Company | Electrostatic spraying of particulate material |
WO2001064273A2 (en) * | 2000-03-01 | 2001-09-07 | Glaxo Group Limited | Metered dose inhaler |
WO2001073431A2 (en) | 2000-03-24 | 2001-10-04 | Delsys Pharmaceutical Corporation | Biomedical assay device |
US20020136772A1 (en) * | 2001-03-26 | 2002-09-26 | Tai-Nang Huang | Polymer synthesis |
US20020136978A1 (en) * | 2001-03-26 | 2002-09-26 | Tai-Nang Huang | Transfer of arrayed chemical compositions |
US20020144678A1 (en) * | 1998-02-23 | 2002-10-10 | Warby Richard John | Drug delivery devices |
US6511712B1 (en) | 1998-06-10 | 2003-01-28 | Delsys Pharmaceutical | Methods using dry powder deposition apparatuses |
US6575161B1 (en) * | 1998-07-30 | 2003-06-10 | Microdrug Ag | Powder classification device |
US6591833B2 (en) * | 1996-06-10 | 2003-07-15 | Delsys Pharmaceutical Corp. | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US20030145850A1 (en) * | 2000-03-01 | 2003-08-07 | Hailey Mark Andrew | Metered dose inhaler |
US20030150447A1 (en) * | 2000-03-01 | 2003-08-14 | Hailey Mark Andrew | Metered dose inhaler |
US20030178440A1 (en) * | 2002-01-22 | 2003-09-25 | Bespak Plc | Dispensing Apparatus for Delivering Powdered Product |
US6626170B1 (en) * | 1998-08-26 | 2003-09-30 | Bespak Plc | Drug delivery devices |
US20030183223A1 (en) * | 2000-03-01 | 2003-10-02 | Hailey Andrew Mark | Metered dose inhaler |
US20030183224A1 (en) * | 2000-03-01 | 2003-10-02 | Hailey Mark Andrew | Metered dose inhaler |
US20030192917A1 (en) * | 2002-01-15 | 2003-10-16 | Bespak Plc | Valves for Dispensers |
US20040025877A1 (en) * | 2002-05-10 | 2004-02-12 | Crowder Timothy M. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
US20040055598A1 (en) * | 2002-05-10 | 2004-03-25 | Crowder Timothy M. | Apparatus, systems and related methods for processing, dispensing and/or evaluating non-pharmaceutical dry powders |
US20040055602A1 (en) * | 1998-03-19 | 2004-03-25 | Riebe Michael Thomas | Valve for aerosol container |
US20040071906A1 (en) * | 2000-12-13 | 2004-04-15 | Derek Brewis | Surface modification process |
US20040173211A1 (en) * | 2003-01-14 | 2004-09-09 | Boehringer Ingelheim International Gmbh | Powder inhaler |
US6866039B1 (en) | 2000-10-12 | 2005-03-15 | Bespak Plc | Dispensing apparatus |
US20050103337A1 (en) * | 2003-10-27 | 2005-05-19 | Anthony James Hickey | Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances |
US20050109659A1 (en) * | 2003-10-27 | 2005-05-26 | Hickey Anthony J. | Blister packages with frames and associated methods of fabricating dry powder drug containment systems |
US20050158394A1 (en) * | 2000-02-28 | 2005-07-21 | Vectura Limited | Delivery of oral drugs |
US20050267628A1 (en) * | 2002-05-10 | 2005-12-01 | Oriel Therapeutics, Inc. | Dry powder dose filling systems and related methods |
US6985798B2 (en) | 2002-05-10 | 2006-01-10 | Oriel Therapeutics, Inc. | Dry powder dose filling systems and related methods |
US20060076010A1 (en) * | 2002-12-18 | 2006-04-13 | King Michael L | Drug delivery system with vented mouthpiece |
US20060174206A1 (en) * | 2005-01-31 | 2006-08-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Shared image device synchronization or designation |
US7086571B2 (en) | 2001-04-30 | 2006-08-08 | Bespak Plc | Valves for pressurized dispensing containers |
US7118010B2 (en) | 2002-05-10 | 2006-10-10 | Oriel Therapeutics, Inc. | Apparatus, systems and related methods for dispensing and /or evaluating dry powders |
US20080021374A1 (en) * | 2004-05-13 | 2008-01-24 | Sousaku Kawata | Apparatus for Hemostasis and Adhesion Prevention for Use in Endoscopic Surgery |
US20090071478A1 (en) * | 2007-09-17 | 2009-03-19 | General Electric Company | Ventilator |
US20110120464A1 (en) * | 2008-01-11 | 2011-05-26 | Innovata Biomed Limited | Inhalers |
US20120138713A1 (en) * | 2009-03-31 | 2012-06-07 | Boehringer Ingelheim International Gmbh | Method for coating a surface of a component |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ352197A3 (en) | 1995-05-09 | 1998-04-15 | Colorcon Limited | Electrostatic coating process and apparatus for making the same |
US7008668B2 (en) * | 1995-05-09 | 2006-03-07 | Phoqus Pharmaceuticals Limited | Powder coating composition for electrostatic coating of pharmaceutical substrates |
GB9623634D0 (en) * | 1996-11-13 | 1997-01-08 | Bpsi Holdings Inc | Method and apparatus for the coating of substrates for pharmaceutical use |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
GB0002305D0 (en) * | 2000-02-01 | 2000-03-22 | Phoqus Limited | Power material for electrostatic application |
IL160928A0 (en) * | 2001-10-19 | 2004-08-31 | Maxim Pharm Inc | Use of histamine to treat liver disease |
WO2003080149A2 (en) | 2002-03-20 | 2003-10-02 | Mannkind Corporation | Inhalation apparatus |
SE525027C2 (en) * | 2002-04-12 | 2004-11-16 | Microdrug Ag | Device comprising a powder air grinder |
WO2004017913A2 (en) * | 2002-08-22 | 2004-03-04 | Nutrition 21, Inc. | Arginine silicate inositol complex and use thereof |
DE10300982A1 (en) * | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | powder inhaler |
JP2007517537A (en) * | 2003-06-13 | 2007-07-05 | アドバンスト インハレーション リサーチ,インコーポレイテッド | Low dosage pharmaceutical powder for inhalation |
GB2420297B (en) * | 2003-06-18 | 2006-11-15 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
US20050171192A1 (en) * | 2003-12-11 | 2005-08-04 | Gehlsen Kurt R. | Use of histamine to treat bone disease |
GB0330171D0 (en) * | 2003-12-30 | 2004-02-04 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
GB0407312D0 (en) * | 2004-03-31 | 2004-05-05 | Phoqus Pharmaceuticals Ltd | Method and apparatus for the application of powder material to substrates |
WO2006009975A2 (en) * | 2004-06-22 | 2006-01-26 | Maxim Pharmaceuticals, Inc. | Histamine to treat disorders affecting muscle function |
JP5078014B2 (en) | 2004-08-20 | 2012-11-21 | マンカインド コーポレイション | Catalytic reaction of diketopiperazine synthesis. |
HUE026797T2 (en) | 2004-08-23 | 2016-07-28 | Mannkind Corp | Diketopiperazine salts for drug delivery |
KR20120060245A (en) | 2005-09-14 | 2012-06-11 | 맨카인드 코포레이션 | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
EP2497484A3 (en) | 2006-02-22 | 2012-11-07 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
EP2001535A1 (en) * | 2006-03-21 | 2008-12-17 | Bang & Olufsen Medicom A/S | Inhaler flow channel |
US8227027B2 (en) * | 2007-12-07 | 2012-07-24 | Presspart Gmbh & Co. Kg | Method for applying a polymer coating to an internal surface of a container |
EP3281663B8 (en) | 2008-06-13 | 2022-09-21 | MannKind Corporation | Breath powered dry powder inhaler for drug delivery |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
US9364619B2 (en) | 2008-06-20 | 2016-06-14 | Mannkind Corporation | Interactive apparatus and method for real-time profiling of inhalation efforts |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
CA2754595C (en) | 2009-03-11 | 2017-06-27 | Mannkind Corporation | Apparatus, system and method for measuring resistance of an inhaler |
WO2010144789A2 (en) | 2009-06-12 | 2010-12-16 | Mannkind Corporation | Diketopiperazine microparticles with defined specific surface areas |
CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
PT105065B (en) * | 2010-04-26 | 2012-07-31 | Hovione Farmaciencia S A | A SIMPLE INHALER OF CAPSULES |
AU2011271097B2 (en) | 2010-06-21 | 2014-11-27 | Mannkind Corporation | Dry powder drug delivery system and methods |
CN105667994B (en) | 2011-04-01 | 2018-04-06 | 曼金德公司 | Blister package for pharmaceutical kit |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
KR20140095483A (en) | 2011-10-24 | 2014-08-01 | 맨카인드 코포레이션 | Methods and compositions for treating pain |
DK2872205T3 (en) | 2012-07-12 | 2017-02-27 | Mannkind Corp | DRY POWDER FORMAL ADMINISTRATION SYSTEM |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
KR102499439B1 (en) | 2013-03-15 | 2023-02-13 | 맨카인드 코포레이션 | Microcrystalline diketopiperazine compositions and methods |
WO2015010092A1 (en) | 2013-07-18 | 2015-01-22 | Mannkind Corporation | Heat-stable dry powder pharmaceutical compositions and methods |
JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
US11191735B2 (en) | 2015-03-13 | 2021-12-07 | Nutrition 21, Llc | Arginine silicate for periodontal disease |
US20170135969A1 (en) | 2015-11-12 | 2017-05-18 | Jds Therapeutics, Llc | Topical arginine-silicate-inositol for wound healing |
CN109890384A (en) | 2016-09-01 | 2019-06-14 | Jds治疗有限公司 | Biotin magnesium compositions and application method |
EP3873331A4 (en) | 2018-11-02 | 2022-08-24 | Nutrition 21, LLC | Compositions containing inositol-stabilized arginine silicate complexes and inositol for improving cognitive function in video gamers |
WO2021127048A1 (en) | 2019-12-16 | 2021-06-24 | Nutrition 21, Llc | Methods of production of arginine-silicate complexes |
Citations (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2603216A (en) * | 1952-07-15 | Powder inhaler | ||
US2604094A (en) * | 1949-06-25 | 1952-07-22 | Schenley Ind Inc | Inhaler |
US3831606A (en) * | 1971-02-19 | 1974-08-27 | Alza Corp | Auto inhaler |
US3971377A (en) * | 1974-06-10 | 1976-07-27 | Alza Corporation | Medicament dispensing process for inhalation therapy |
US4047525A (en) * | 1975-01-17 | 1977-09-13 | Schering Aktiengesellschaft | Inhalator for agglomeratable pulverulent solids |
US4069086A (en) * | 1975-12-15 | 1978-01-17 | Hoffmann-La Roche Inc. | Novel dosage form |
US4072129A (en) * | 1976-04-27 | 1978-02-07 | National Research Development Corporation | Electrostatic powder deposition |
US4105027A (en) * | 1975-06-13 | 1978-08-08 | Syntex Puerto Rico, Inc. | Inhalation device |
US4160257A (en) * | 1978-07-17 | 1979-07-03 | Dennison Manufacturing Company | Three electrode system in the generation of electrostatic images |
US4197289A (en) * | 1975-12-15 | 1980-04-08 | Hoffmann-La Roche Inc. | Novel dosage forms |
US4252848A (en) * | 1977-04-11 | 1981-02-24 | Rca Corporation | Perfluorinated polymer thin films |
GB2064334A (en) * | 1979-10-16 | 1981-06-17 | Glaxo Group Ltd | Inhalation valve for administering powdered medicaments |
US4332789A (en) * | 1975-12-15 | 1982-06-01 | Hoffmann-La Roche Inc. | Pharmaceutical unit dosage forms |
US4353365A (en) * | 1979-12-06 | 1982-10-12 | Glaxo Group Limited | Device for dispensing medicaments |
EP0129985A1 (en) * | 1983-05-24 | 1985-01-02 | Glaxo Group Limited | Inhalation device |
US4570630A (en) * | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
US4627432A (en) * | 1982-10-08 | 1986-12-09 | Glaxo Group Limited | Devices for administering medicaments to patients |
US4664107A (en) * | 1983-10-28 | 1987-05-12 | Minnesota Mining And Manufacturing Company | Inhalation activatable dispensers |
US4685620A (en) * | 1985-09-30 | 1987-08-11 | The University Of Georgia Research Foundation Inc. | Low-volume electrostatic spraying |
US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
US4795644A (en) * | 1987-08-03 | 1989-01-03 | Merck & Co., Inc. | Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins |
US4811731A (en) * | 1985-07-30 | 1989-03-14 | Glaxo Group Limited | Devices for administering medicaments to patients |
US4889114A (en) * | 1983-12-17 | 1989-12-26 | Boehringer Ingelheim Kg | Powdered pharmaceutical inhaler |
US4917978A (en) * | 1989-01-23 | 1990-04-17 | Thomson Consumer Electronics, Inc. | Method of electrophotographically manufacturing a luminescent screen assembly having increased adherence for a CRT |
US4921767A (en) * | 1988-12-21 | 1990-05-01 | Rca Licensing Corp. | Method of electrophotographically manufacturing a luminescent screen assembly for a cathode-ray-tube |
US4921727A (en) * | 1988-12-21 | 1990-05-01 | Rca Licensing Corporation | Surface treatment of silica-coated phosphor particles and method for a CRT screen |
US4971257A (en) * | 1989-11-27 | 1990-11-20 | Marc Birge | Electrostatic aerosol spray can assembly |
US5028501A (en) * | 1989-06-14 | 1991-07-02 | Rca Licensing Corp. | Method of manufacturing a luminescent screen assembly using a dry-powdered filming material |
US5031610A (en) * | 1987-05-12 | 1991-07-16 | Glaxo Inc. | Inhalation device |
GB2242134A (en) * | 1990-03-02 | 1991-09-25 | Glaxo Group Ltd | Inhalation device |
US5115803A (en) * | 1990-08-31 | 1992-05-26 | Minnesota Mining And Manufacturing Company | Aerosol actuator providing increased respirable fraction |
US5161524A (en) * | 1991-08-02 | 1992-11-10 | Glaxo Inc. | Dosage inhalator with air flow velocity regulating means |
US5176132A (en) * | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
WO1993009832A1 (en) * | 1991-11-12 | 1993-05-27 | Minnesota Mining And Manufacturing Company | Inhalation device |
US5239993A (en) * | 1992-08-26 | 1993-08-31 | Glaxo Inc. | Dosage inhalator providing optimized compound inhalation trajectory |
US5243970A (en) * | 1991-04-15 | 1993-09-14 | Schering Corporation | Dosing device for administering metered amounts of powdered medicaments to patients |
US5263475A (en) * | 1991-03-21 | 1993-11-23 | Ciba-Geigy Corp. | Inhaler |
WO1993024166A2 (en) * | 1992-06-04 | 1993-12-09 | Glaxo Group Limited | Inhalation device |
US5278588A (en) * | 1991-05-17 | 1994-01-11 | Delphax Systems | Electrographic printing device |
WO1994006497A1 (en) * | 1992-09-11 | 1994-03-31 | Glaxo Group Limited | Inhalation device |
US5301666A (en) * | 1991-12-14 | 1994-04-12 | Asta Medica Aktiengesellschaft | Powder inhaler |
WO1994008552A2 (en) * | 1992-10-19 | 1994-04-28 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
WO1994013271A1 (en) * | 1992-12-11 | 1994-06-23 | Astra Aktiebolag | System for dispensing pharmaceutically active compounds |
US5327883A (en) * | 1991-05-20 | 1994-07-12 | Dura Pharmaceuticals, Inc. | Apparatus for aerosolizing powdered medicine and process and using |
GB2274273A (en) * | 1990-03-02 | 1994-07-20 | Glaxo Group Ltd | Medicament pack |
WO1994023772A2 (en) * | 1993-04-06 | 1994-10-27 | Minnesota Mining And Manufacturing Company | Deagglomerators for dry powder inhalers |
WO1995000127A1 (en) * | 1993-06-24 | 1995-01-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
EP0642992A2 (en) * | 1993-08-27 | 1995-03-15 | Ciba-Geigy Ag | Metered aerosol with CFC free propellant and dosing valve as well as application thereof |
US5415162A (en) * | 1994-01-18 | 1995-05-16 | Glaxo Inc. | Multi-dose dry powder inhalation device |
US5462701A (en) * | 1992-04-08 | 1995-10-31 | Basf Magnetics Gmbh | Sheet-like polyethylene terephthalate materials having slight surface roughness, their preparation and their use |
US5507281A (en) * | 1990-08-30 | 1996-04-16 | Boehringer Ingelheim Kg | Device for initiating a mechanical switching operation in synchronism with the breathing |
US5512131A (en) * | 1993-10-04 | 1996-04-30 | President And Fellows Of Harvard College | Formation of microstamped patterns on surfaces and derivative articles |
US5619984A (en) * | 1989-04-28 | 1997-04-15 | Astra Aktiebolag | Dry powder inhalation device having a powder-loaded elongate carrier |
US5652079A (en) * | 1994-12-06 | 1997-07-29 | Ricoh Company, Ltd. | Carrier for dry two-component developer and method of producing the same |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2936814A (en) * | 1956-06-25 | 1960-05-17 | Goodyear Tire & Rubber | Method of embedding particles in plastic sheet material |
US3622422A (en) * | 1965-12-15 | 1971-11-23 | Kendall & Co | Process for producing a nonwoven fabric |
DE3622559A1 (en) * | 1986-07-04 | 1987-05-21 | Schlegel Lining Tech Gmbh | METHOD FOR FINISHING THE SURFACE OF A FILM OF WELDABLE POLYMER MATERIAL WITH PROJECTED PRESSURES AND FILM PRODUCED BY THIS METHOD |
US5039561A (en) * | 1986-08-25 | 1991-08-13 | Minnesota Mining And Manufacturing Company | Method for preparing an article having surface layer of uniformly oriented, crystalline, organic microstructures |
EP0705614B1 (en) * | 1989-04-28 | 2002-09-25 | Riker Laboratories, Inc. | Dry powder inhalation device |
US5152456A (en) * | 1989-12-12 | 1992-10-06 | Bespak, Plc | Dispensing apparatus having a perforate outlet member and a vibrating device |
US5192548A (en) * | 1990-04-30 | 1993-03-09 | Riker Laboratoires, Inc. | Device |
IL98441A (en) * | 1990-06-14 | 1995-12-31 | Rhone Poulenc Rorer Ltd | Powder inhalers |
DE59106431D1 (en) * | 1990-06-28 | 1995-10-12 | Boehringer Ingelheim Kg | DEVICE AND METHOD FOR POWDER DOSING. |
DE4142238A1 (en) * | 1991-12-20 | 1993-06-24 | Boehringer Ingelheim Kg | POWDER INHALATOR WITH POWDER SUPPORT FROM REGULAR MICROSTRUCTURES |
GB2269992A (en) * | 1992-08-14 | 1994-03-02 | Rh Ne Poulenc Rorer Limited | Powder inhalation formulations |
KR960701672A (en) * | 1993-03-03 | 1996-03-28 | 윌리엄 피. 알트만 | DRY POWDER INHALATOR MEDICAMENT CARRIER |
GB9322014D0 (en) * | 1993-10-26 | 1993-12-15 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
US5388573A (en) * | 1993-12-02 | 1995-02-14 | Tenax Corporation | Dry powder inhalator medicament carrier |
US5647347A (en) * | 1994-10-21 | 1997-07-15 | Glaxo Wellcome Inc. | Medicament carrier for dry powder inhalator |
US5612081A (en) * | 1994-11-25 | 1997-03-18 | Netlon Limited | Applying grit particles to a continuous web |
GB9501841D0 (en) * | 1995-01-31 | 1995-03-22 | Co Ordinated Drug Dev | Improvements in and relating to carrier particles for use in dry powder inhalers |
GB9515182D0 (en) * | 1995-07-24 | 1995-09-20 | Co Ordinated Drug Dev | Improvements in and relating to powders for use in dry powder inhalers |
US5728424A (en) * | 1996-04-10 | 1998-03-17 | Gse Lining Technology, Inc. | Method for forming a textured surface on a geomembrane |
US5871010A (en) * | 1996-06-10 | 1999-02-16 | Sarnoff Corporation | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
-
1996
- 1996-06-10 US US08/661,213 patent/US5871010A/en not_active Expired - Fee Related
-
1998
- 1998-12-11 US US09/210,214 patent/US6298847B1/en not_active Expired - Fee Related
-
2001
- 2001-02-13 US US09/782,419 patent/US6591833B2/en not_active Expired - Fee Related
Patent Citations (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2603216A (en) * | 1952-07-15 | Powder inhaler | ||
US2604094A (en) * | 1949-06-25 | 1952-07-22 | Schenley Ind Inc | Inhaler |
US3831606A (en) * | 1971-02-19 | 1974-08-27 | Alza Corp | Auto inhaler |
US3971377A (en) * | 1974-06-10 | 1976-07-27 | Alza Corporation | Medicament dispensing process for inhalation therapy |
US4047525A (en) * | 1975-01-17 | 1977-09-13 | Schering Aktiengesellschaft | Inhalator for agglomeratable pulverulent solids |
US4105027A (en) * | 1975-06-13 | 1978-08-08 | Syntex Puerto Rico, Inc. | Inhalation device |
US4332789A (en) * | 1975-12-15 | 1982-06-01 | Hoffmann-La Roche Inc. | Pharmaceutical unit dosage forms |
US4197289A (en) * | 1975-12-15 | 1980-04-08 | Hoffmann-La Roche Inc. | Novel dosage forms |
US4069086A (en) * | 1975-12-15 | 1978-01-17 | Hoffmann-La Roche Inc. | Novel dosage form |
US4072129A (en) * | 1976-04-27 | 1978-02-07 | National Research Development Corporation | Electrostatic powder deposition |
US4252848A (en) * | 1977-04-11 | 1981-02-24 | Rca Corporation | Perfluorinated polymer thin films |
US4160257A (en) * | 1978-07-17 | 1979-07-03 | Dennison Manufacturing Company | Three electrode system in the generation of electrostatic images |
GB2064334A (en) * | 1979-10-16 | 1981-06-17 | Glaxo Group Ltd | Inhalation valve for administering powdered medicaments |
US4353365A (en) * | 1979-12-06 | 1982-10-12 | Glaxo Group Limited | Device for dispensing medicaments |
US4627432A (en) * | 1982-10-08 | 1986-12-09 | Glaxo Group Limited | Devices for administering medicaments to patients |
US4778054A (en) * | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
EP0129985A1 (en) * | 1983-05-24 | 1985-01-02 | Glaxo Group Limited | Inhalation device |
US4570630A (en) * | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
US4664107A (en) * | 1983-10-28 | 1987-05-12 | Minnesota Mining And Manufacturing Company | Inhalation activatable dispensers |
US4889114A (en) * | 1983-12-17 | 1989-12-26 | Boehringer Ingelheim Kg | Powdered pharmaceutical inhaler |
US4811731A (en) * | 1985-07-30 | 1989-03-14 | Glaxo Group Limited | Devices for administering medicaments to patients |
US5035237A (en) * | 1985-07-30 | 1991-07-30 | Newell Robert E | Devices for administering medicaments to patients |
US4685620A (en) * | 1985-09-30 | 1987-08-11 | The University Of Georgia Research Foundation Inc. | Low-volume electrostatic spraying |
US5031610A (en) * | 1987-05-12 | 1991-07-16 | Glaxo Inc. | Inhalation device |
US4795644A (en) * | 1987-08-03 | 1989-01-03 | Merck & Co., Inc. | Device for pH independent release of drugs through the Donnan-like influence of charged insoluble resins |
US4921767A (en) * | 1988-12-21 | 1990-05-01 | Rca Licensing Corp. | Method of electrophotographically manufacturing a luminescent screen assembly for a cathode-ray-tube |
US4921727A (en) * | 1988-12-21 | 1990-05-01 | Rca Licensing Corporation | Surface treatment of silica-coated phosphor particles and method for a CRT screen |
US4917978A (en) * | 1989-01-23 | 1990-04-17 | Thomson Consumer Electronics, Inc. | Method of electrophotographically manufacturing a luminescent screen assembly having increased adherence for a CRT |
US5619984A (en) * | 1989-04-28 | 1997-04-15 | Astra Aktiebolag | Dry powder inhalation device having a powder-loaded elongate carrier |
US5176132A (en) * | 1989-05-31 | 1993-01-05 | Fisons Plc | Medicament inhalation device and formulation |
US5028501A (en) * | 1989-06-14 | 1991-07-02 | Rca Licensing Corp. | Method of manufacturing a luminescent screen assembly using a dry-powdered filming material |
US4971257A (en) * | 1989-11-27 | 1990-11-20 | Marc Birge | Electrostatic aerosol spray can assembly |
GB2242134A (en) * | 1990-03-02 | 1991-09-25 | Glaxo Group Ltd | Inhalation device |
GB2274273A (en) * | 1990-03-02 | 1994-07-20 | Glaxo Group Ltd | Medicament pack |
US5507281A (en) * | 1990-08-30 | 1996-04-16 | Boehringer Ingelheim Kg | Device for initiating a mechanical switching operation in synchronism with the breathing |
US5115803A (en) * | 1990-08-31 | 1992-05-26 | Minnesota Mining And Manufacturing Company | Aerosol actuator providing increased respirable fraction |
US5263475A (en) * | 1991-03-21 | 1993-11-23 | Ciba-Geigy Corp. | Inhaler |
US5243970A (en) * | 1991-04-15 | 1993-09-14 | Schering Corporation | Dosing device for administering metered amounts of powdered medicaments to patients |
US5278588A (en) * | 1991-05-17 | 1994-01-11 | Delphax Systems | Electrographic printing device |
US5327883A (en) * | 1991-05-20 | 1994-07-12 | Dura Pharmaceuticals, Inc. | Apparatus for aerosolizing powdered medicine and process and using |
US5161524A (en) * | 1991-08-02 | 1992-11-10 | Glaxo Inc. | Dosage inhalator with air flow velocity regulating means |
WO1993009832A1 (en) * | 1991-11-12 | 1993-05-27 | Minnesota Mining And Manufacturing Company | Inhalation device |
US5301666A (en) * | 1991-12-14 | 1994-04-12 | Asta Medica Aktiengesellschaft | Powder inhaler |
US5462701A (en) * | 1992-04-08 | 1995-10-31 | Basf Magnetics Gmbh | Sheet-like polyethylene terephthalate materials having slight surface roughness, their preparation and their use |
WO1993024166A2 (en) * | 1992-06-04 | 1993-12-09 | Glaxo Group Limited | Inhalation device |
US5239993A (en) * | 1992-08-26 | 1993-08-31 | Glaxo Inc. | Dosage inhalator providing optimized compound inhalation trajectory |
WO1994006497A1 (en) * | 1992-09-11 | 1994-03-31 | Glaxo Group Limited | Inhalation device |
WO1994008552A2 (en) * | 1992-10-19 | 1994-04-28 | Dura Pharmaceuticals, Inc. | Dry powder inhaler |
WO1994013271A1 (en) * | 1992-12-11 | 1994-06-23 | Astra Aktiebolag | System for dispensing pharmaceutically active compounds |
WO1994023772A2 (en) * | 1993-04-06 | 1994-10-27 | Minnesota Mining And Manufacturing Company | Deagglomerators for dry powder inhalers |
WO1995000127A1 (en) * | 1993-06-24 | 1995-01-05 | Astra Aktiebolag | Therapeutic preparation for inhalation |
EP0642992A2 (en) * | 1993-08-27 | 1995-03-15 | Ciba-Geigy Ag | Metered aerosol with CFC free propellant and dosing valve as well as application thereof |
US5512131A (en) * | 1993-10-04 | 1996-04-30 | President And Fellows Of Harvard College | Formation of microstamped patterns on surfaces and derivative articles |
US5415162A (en) * | 1994-01-18 | 1995-05-16 | Glaxo Inc. | Multi-dose dry powder inhalation device |
US5652079A (en) * | 1994-12-06 | 1997-07-29 | Ricoh Company, Ltd. | Carrier for dry two-component developer and method of producing the same |
Non-Patent Citations (18)
Title |
---|
Donald A. Seanor, Triboelectrification of Polymers in K.C. Frisch and A. Patsis, Electrical Properties of Polymers (Technomic Pubcations, Westport, CT) p.p. 37 58. * |
Donald A. Seanor, Triboelectrification of Polymers in K.C. Frisch and A. Patsis, Electrical Properties of Polymers (Technomic Pubcations, Westport, CT) p.p. 37-58. |
J. F. Daviet et al., Electrostatic Clamping Applied to Semiconductor Plasma Processing, I. Theoretical Modeling, J. Electrochem. Soc., vol. 140, No. 11, pp. 3245 3256 (Nov. 1993). * |
J. -F. Daviet et al., Electrostatic Clamping Applied to Semiconductor Plasma Processing, I. Theoretical Modeling, J. Electrochem. Soc., vol. 140, No. 11, pp. 3245-3256 (Nov. 1993). |
J. F. Daviet et al., Electrostatic Clamping Applied to Semiconductor Plasma Processing, II. Experimental Results, J. Electrochem. Soc., vol. 140, No. 11, pp. 3256 3261 (Nov. 1993). * |
J. -F. Daviet et al., Electrostatic Clamping Applied to Semiconductor Plasma Processing, II. Experimental Results, J. Electrochem. Soc., vol. 140, No. 11, pp. 3256-3261 (Nov. 1993). |
John Field, Electrostatic Wafer Clamping for Next Generation Manufacturing, Solid State Technology, pp. 91 98 (Sep. 1994). * |
John Field, Electrostatic Wafer Clamping for Next-Generation Manufacturing, Solid State Technology, pp. 91-98 (Sep. 1994). |
Larry D. Harsough, Electrostatic Wafer Holding, Solid State Technology, pp. 87 90 (Jan. 1993). * |
Larry D. Harsough, Electrostatic Wafer Holding, Solid State Technology, pp. 87-90 (Jan. 1993). |
Mamoru Nakasuji et al., Low Voltage and High Speed Operating Electrostatic Wafer Chuck Using Sputtered Tantalum Oxide Membrane, J. Vac. Sci. Technol. A 12(5) pp. 2834 2839 (Sep./Oct. 1994). * |
Mamoru Nakasuji et al., Low Voltage and High Speed Operating Electrostatic Wafer Chuck Using Sputtered Tantalum Oxide Membrane, J. Vac. Sci. Technol. A 12(5) pp. 2834-2839 (Sep./Oct. 1994). |
Peter Singer, Electrostatic Chucks in Wafer Processing, Semiconductor International, pp. 57 64 (Apr. 1995). * |
Peter Singer, Electrostatic Chucks in Wafer Processing, Semiconductor International, pp. 57-64 (Apr. 1995). |
T. Watanabe et al., Electrostatic Charge Distribution in The Dielectric Layer of Alumina Electrostatic Chuck, Journal of Materials Science, vol. 29, pp. 3510 3616 (1994). * |
T. Watanabe et al., Electrostatic Charge Distribution in The Dielectric Layer of Alumina Electrostatic Chuck, Journal of Materials Science, vol. 29, pp. 3510-3616 (1994). |
Toshiya Watanabe et al., Electrostatic Force and Absorption Current of Alumina Electrostatic Chuck, Jpn. J. Appl. Phys. vol. 31, pp. 2145 2150 (1992). * |
Toshiya Watanabe et al., Electrostatic Force and Absorption Current of Alumina Electrostatic Chuck, Jpn. J. Appl. Phys. vol. 31, pp. 2145-2150 (1992). |
Cited By (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6138671A (en) * | 1994-10-04 | 2000-10-31 | The Procter & Gamble Company | Electrostatic spraying of particulate material |
US6591833B2 (en) * | 1996-06-10 | 2003-07-15 | Delsys Pharmaceutical Corp. | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
US20030101993A1 (en) * | 1998-02-23 | 2003-06-05 | Warby Richard John | Drug delivery devices |
US20050279352A1 (en) * | 1998-02-23 | 2005-12-22 | Bespak Plc | Drug delivery devices |
US20020144678A1 (en) * | 1998-02-23 | 2002-10-10 | Warby Richard John | Drug delivery devices |
US20070131226A1 (en) * | 1998-02-23 | 2007-06-14 | Warby Richard J | Drug Delivery Devices |
US20040055602A1 (en) * | 1998-03-19 | 2004-03-25 | Riebe Michael Thomas | Valve for aerosol container |
US20080098600A1 (en) * | 1998-03-19 | 2008-05-01 | Riebe Michael T | Valve for Aerosol Container |
US6720024B2 (en) | 1998-06-10 | 2004-04-13 | Delsys Pharmaceutical Corporation | Methods using dry powder deposition apparatuses |
WO1999063972A1 (en) | 1998-06-10 | 1999-12-16 | Delsys Pharmaceutical Corporation | Pharmaceutical product and methods and apparatus for making same |
US6511712B1 (en) | 1998-06-10 | 2003-01-28 | Delsys Pharmaceutical | Methods using dry powder deposition apparatuses |
US6575161B1 (en) * | 1998-07-30 | 2003-06-10 | Microdrug Ag | Powder classification device |
US6626170B1 (en) * | 1998-08-26 | 2003-09-30 | Bespak Plc | Drug delivery devices |
US6397840B1 (en) * | 1998-11-05 | 2002-06-04 | Delsys Pharmaceutical Corporation | Dry powder dispensing device |
WO2000027456A1 (en) | 1998-11-05 | 2000-05-18 | Delsys Pharmaceutical Corporation | Method of depositing a dry powder and dispensing device |
US20050158394A1 (en) * | 2000-02-28 | 2005-07-21 | Vectura Limited | Delivery of oral drugs |
EP1941868A2 (en) | 2000-02-28 | 2008-07-09 | PharmaKodex Limited | Improvements in or relating to the delivery of oral drugs |
US20030150447A1 (en) * | 2000-03-01 | 2003-08-14 | Hailey Mark Andrew | Metered dose inhaler |
US20030183223A1 (en) * | 2000-03-01 | 2003-10-02 | Hailey Andrew Mark | Metered dose inhaler |
US20030183224A1 (en) * | 2000-03-01 | 2003-10-02 | Hailey Mark Andrew | Metered dose inhaler |
WO2001064273A3 (en) * | 2000-03-01 | 2002-03-28 | Glaxo Group Ltd | Metered dose inhaler |
WO2001064273A2 (en) * | 2000-03-01 | 2001-09-07 | Glaxo Group Limited | Metered dose inhaler |
US20030145850A1 (en) * | 2000-03-01 | 2003-08-07 | Hailey Mark Andrew | Metered dose inhaler |
WO2001073431A2 (en) | 2000-03-24 | 2001-10-04 | Delsys Pharmaceutical Corporation | Biomedical assay device |
US6866039B1 (en) | 2000-10-12 | 2005-03-15 | Bespak Plc | Dispensing apparatus |
US20040071906A1 (en) * | 2000-12-13 | 2004-04-15 | Derek Brewis | Surface modification process |
US20060083879A1 (en) * | 2000-12-13 | 2006-04-20 | Derek Brewis | Surface modification process |
US6838447B2 (en) | 2001-03-26 | 2005-01-04 | Linden Technologies, Inc. | Particulate compositions for chemical synthesis |
US20040013573A1 (en) * | 2001-03-26 | 2004-01-22 | Tai-Nang Huang | Polymer synthesis apparatus |
US20020136772A1 (en) * | 2001-03-26 | 2002-09-26 | Tai-Nang Huang | Polymer synthesis |
US6855501B2 (en) | 2001-03-26 | 2005-02-15 | Linden Technologies, Inc. | Transfer of arrayed chemical compositions |
US20020136978A1 (en) * | 2001-03-26 | 2002-09-26 | Tai-Nang Huang | Transfer of arrayed chemical compositions |
US20020168669A1 (en) * | 2001-03-26 | 2002-11-14 | Tai-Nang Huang | Patterned polymer synthesis |
US7086571B2 (en) | 2001-04-30 | 2006-08-08 | Bespak Plc | Valves for pressurized dispensing containers |
US20030192917A1 (en) * | 2002-01-15 | 2003-10-16 | Bespak Plc | Valves for Dispensers |
US6945953B2 (en) | 2002-01-22 | 2005-09-20 | Bespak Plc | Dispensing apparatus for delivering powdered product |
US20030178440A1 (en) * | 2002-01-22 | 2003-09-25 | Bespak Plc | Dispensing Apparatus for Delivering Powdered Product |
US6889690B2 (en) | 2002-05-10 | 2005-05-10 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
US20040055598A1 (en) * | 2002-05-10 | 2004-03-25 | Crowder Timothy M. | Apparatus, systems and related methods for processing, dispensing and/or evaluating non-pharmaceutical dry powders |
US7677411B2 (en) | 2002-05-10 | 2010-03-16 | Oriel Therapeutics, Inc. | Apparatus, systems and related methods for processing, dispensing and/or evaluatingl dry powders |
US6985798B2 (en) | 2002-05-10 | 2006-01-10 | Oriel Therapeutics, Inc. | Dry powder dose filling systems and related methods |
US20050126569A1 (en) * | 2002-05-10 | 2005-06-16 | Crowder Timothy M. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
US7520278B2 (en) | 2002-05-10 | 2009-04-21 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
US7118010B2 (en) | 2002-05-10 | 2006-10-10 | Oriel Therapeutics, Inc. | Apparatus, systems and related methods for dispensing and /or evaluating dry powders |
US20050267628A1 (en) * | 2002-05-10 | 2005-12-01 | Oriel Therapeutics, Inc. | Dry powder dose filling systems and related methods |
US7428446B2 (en) | 2002-05-10 | 2008-09-23 | Oriel Therapeutics, Inc. | Dry powder dose filling systems and related methods |
US20040025877A1 (en) * | 2002-05-10 | 2004-02-12 | Crowder Timothy M. | Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages |
US20060076010A1 (en) * | 2002-12-18 | 2006-04-13 | King Michael L | Drug delivery system with vented mouthpiece |
US20040173211A1 (en) * | 2003-01-14 | 2004-09-09 | Boehringer Ingelheim International Gmbh | Powder inhaler |
US7451761B2 (en) | 2003-10-27 | 2008-11-18 | Oriel Therapeutics, Inc. | Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances |
US7377277B2 (en) | 2003-10-27 | 2008-05-27 | Oriel Therapeutics, Inc. | Blister packages with frames and associated methods of fabricating dry powder drug containment systems |
US20080197044A1 (en) * | 2003-10-27 | 2008-08-21 | Oriel Therapeutics, Inc. | Blister packages with frames for dry powder drug containment |
US20050109659A1 (en) * | 2003-10-27 | 2005-05-26 | Hickey Anthony J. | Blister packages with frames and associated methods of fabricating dry powder drug containment systems |
US20050103337A1 (en) * | 2003-10-27 | 2005-05-19 | Anthony James Hickey | Dry powder inhalers, related blister package indexing and opening mechanisms, and associated methods of dispensing dry powder substances |
US20080021374A1 (en) * | 2004-05-13 | 2008-01-24 | Sousaku Kawata | Apparatus for Hemostasis and Adhesion Prevention for Use in Endoscopic Surgery |
US20060174206A1 (en) * | 2005-01-31 | 2006-08-03 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Shared image device synchronization or designation |
US20090071478A1 (en) * | 2007-09-17 | 2009-03-19 | General Electric Company | Ventilator |
US20110120464A1 (en) * | 2008-01-11 | 2011-05-26 | Innovata Biomed Limited | Inhalers |
US20120138713A1 (en) * | 2009-03-31 | 2012-06-07 | Boehringer Ingelheim International Gmbh | Method for coating a surface of a component |
US10011906B2 (en) * | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
Also Published As
Publication number | Publication date |
---|---|
US6298847B1 (en) | 2001-10-09 |
US20010004892A1 (en) | 2001-06-28 |
US6591833B2 (en) | 2003-07-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5871010A (en) | Inhaler apparatus with modified surfaces for enhanced release of dry powders | |
US5857456A (en) | Inhaler apparatus with an electronic means for enhanced release of dry powders | |
US6802313B2 (en) | Method and apparatus for electrostatically depositing a medicament powder upon predefined regions of a substrate | |
US6146685A (en) | Method of deposition a dry powder and dispensing device | |
US6399143B1 (en) | Method for clamping and electrostatically coating a substrate | |
WO1996039257A9 (en) | Electrostatically depositing a medicament powder | |
EP0917476B1 (en) | Inhaler apparatus with modified surfaces for enhanced release of dry powders | |
US6671161B2 (en) | Removing dose electric charge | |
US6592930B2 (en) | Particle flow control | |
CN1224365A (en) | Inhaler apparatus with modified surfaces for enhanced release of dry powders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: DAVID SARNOFF RESEARCH CENTER, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DATTA, PABITRA;RIVENBURG, HOWARD CHRISTOPHER;REEL/FRAME:008152/0941;SIGNING DATES FROM 19960731 TO 19960813 |
|
AS | Assignment |
Owner name: DAVID SARNOFF RESEARCH CENTER, INC., NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DATTA, PABITRA;RIVENBURG, HOWARD CHRISTOPHER;DESAI, NITIN V.;REEL/FRAME:008136/0635;SIGNING DATES FROM 19960912 TO 19960913 |
|
AS | Assignment |
Owner name: SARNOFF CORPORATION, NEW JERSEY Free format text: MERGER;ASSIGNOR:DAVID SARNOFF RESEARCH CENTER, INC.;REEL/FRAME:009370/0281 Effective date: 19970404 |
|
FEPP | Fee payment procedure |
Free format text: PAT HOLDER CLAIMS SMALL ENTITY STATUS - SMALL BUSINESS (ORIGINAL EVENT CODE: SM02); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: DELSYS PHARMACEUTICAL CORPORATION, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SARNOFF CORPORATION;REEL/FRAME:009612/0480 Effective date: 19981109 |
|
AS | Assignment |
Owner name: DELSYS PHARMACEUTICAL CORPORATION, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:SARNOFF CORPORATION;REEL/FRAME:009866/0488 Effective date: 19990331 |
|
AS | Assignment |
Owner name: HEALTHCARE VENTURES V, L.P., NEW JERSEY Free format text: SECURITY INTEREST;ASSIGNOR:DELSYS PHARMACEUTICAL CORPORATION;REEL/FRAME:010731/0004 Effective date: 20000326 |
|
FPAY | Fee payment |
Year of fee payment: 4 |
|
REMI | Maintenance fee reminder mailed | ||
FEPP | Fee payment procedure |
Free format text: PAT HOLDER NO LONGER CLAIMS SMALL ENTITY STATUS, ENTITY STATUS SET TO UNDISCOUNTED (ORIGINAL EVENT CODE: STOL); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY |
|
AS | Assignment |
Owner name: SARNOFF CORPORATION, NEW JERSEY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DELSYS PHARMACEUTICAL CORPORATION;REEL/FRAME:016735/0636 Effective date: 20031219 |
|
REMI | Maintenance fee reminder mailed | ||
LAPS | Lapse for failure to pay maintenance fees | ||
STCH | Information on status: patent discontinuation |
Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362 |
|
FP | Lapsed due to failure to pay maintenance fee |
Effective date: 20070216 |